Call for Abstract

International Conference and Expo on Drug Discovery & Designing , will be organized around the theme “Exploring the Research Challenges & Advancements in Drug Discovery & Designing”

Drug Discovery 2015 is comprised of 12 tracks and 78 sessions designed to offer comprehensive sessions that address current issues in Drug Discovery 2015.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Microbial derived constituents in drug discovery
  • Track 1-2Plant derived constituents in drug discovery
  • Track 1-3Therapeutic values and contaminations in plant drugs
  • Track 1-4Phytochemical Screening and Pharmacological Investigation
  • Track 1-5Separation and Identification: HPLC and UV, IR, NMR, Mass spectroscopy
  • Track 1-6Identification of phytoconstituents by spectroscopy and other chemical tests
  • Track 1-7Crystalline structure: X-Ray diffraction
  • Track 1-8Classification And Nomenclature Of Drugs
  • Track 2-1Computer aided drug models in drug discovery
  • Track 2-2Biological evaluation of metal-based drugs
  • Track 2-3Using biomarkers for in silico drug development
  • Track 2-43D models in prediction of side effects of drugs
  • Track 2-5Development of sustained-release drug delivery systems
  • Track 3-1Data mining and knowledge discovery
  • Track 3-2Toxicogenomics / Molecular mechanisms
  • Track 3-3Transduction mechanisms and hormonal modulation at cellular level
  • Track 3-4QSAR Statistical analysis and physicochemical properties
  • Track 3-5Predicting environmental toxicity
  • Track 3-6Regulatory use and validation of QSAR
  • Track 4-1Physicochemical parameters
  • Track 4-2pharmacokinetic and pharmacodynamic parameters
  • Track 4-3Epidemiology of drug interactions
  • Track 4-4Dose regimen and Formulation development
  • Track 4-5Safety Assessment and toxicological studies
  • Track 4-6preclinical studies and exploratory development
  • Track 5-1De-novo drug design
  • Track 5-2Structure based drug design
  • Track 5-3Ligand based drug design
  • Track 5-4Use of Biosensors in drug design
  • Track 5-5Drug design for GPCR targets
  • Track 5-6Computational protein design
  • Track 6-1Novel trends in fragments library design and evaluation (3D, complexity)
  • Track 6-2Fragment-based Approaches Applied to “Tough” Targets (e.g. PPIs)
  • Track 6-3Biophysical methods for fragment library screening (SPR, NMR, ITC)
  • Track 6-4In silico approaches to fragment-based drug design
  • Track 6-5Case studies of fragment-derived compounds in clinical trials
  • Track 7-1Modeling and Designing of Small Compounds
  • Track 7-2Computer graphics in drug design
  • Track 7-3Use of high performance computing
  • Track 7-4Use of X-ray crystallography and NMR spectroscopy in structure determination
  • Track 7-5Molecular and cellular biology
  • Track 7-6Biomarkers in Medical Science
  • Track 7-7In silico molecular design software and tools
  • Track 8-1Receptors and inhibitors
  • Track 8-2Systems biology approach
  • Track 8-3Chemical biology approach
  • Track 8-4Drug transporters in drug discovery
  • Track 8-5Biotechnologyand Nanoparticles in drug discovery
  • Track 8-6Development of radiopharmaceuticals
  • Track 8-7A novel paradigm of drug discovery
  • Track 9-1Drug design: a focus on difficult targets
  • Track 9-2Advances in knowledge-based design
  • Track 9-3Designing molecules with desired activities de novo
  • Track 9-4Protein crystallography case studies
  • Track 9-5The role of natural products in drug design
  • Track 10-1Stem Cells Research
  • Track 10-2Targeting G-couple receptors
  • Track 10-3Orphan and neglected diseases
  • Track 10-4Overcoming drug resistance
  • Track 10-5Novel therapeutic targets
  • Track 10-6Recent advances in computer aided drug design
  • Track 10-7Recent advances in biologics and vaccines development
  • Track 10-8Personalized medicine
  • Track 10-9Recently approved drugs
  • Track 11-1Regulatory Requirements :Legal and ethical Issues
  • Track 11-2Good clinical practices
  • Track 11-3Investigational New Drug application and NDA
  • Track 11-4Abbreviated New Drug Application (ANDA)
  • Track 11-5Preclinical Safety: Discovery & Investigative Safety
  • Track 11-6Patents in pharmaceutical industry
  • Track 11-7Project Planning & Management
  • Track 12-1Computational chemistry case studies
  • Track 12-2Designing and developing scalable chemistry
  • Track 12-3Novel imaging applications in drug discovery
  • Track 12-4Synthetic molecule drug discovery
  • Track 12-5Designing and developing scalable chemistry
  • Track 12-6Novel imaging applications in drug discovery
  • Track 12-7Synthetic molecule drug discovery